iOnctura Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $102M

  • Investors
  • 14

iOnctura General Information

Description

Developer of next-generation bio-molecules intended for the treatment of cancer and fibrosis. The company's bio-molecules include novel therapeutics that modulate key components of immunosuppression in the tumor microenvironment, enabling doctors to identify and treat cancer effectively.

Contact Information

Website
www.ionctura.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Campus Biotech Innovation Park
  • Bâtiment F2, Avenue Sécheron 15
  • 1202 Genève
  • Switzerland
+41 058
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Campus Biotech Innovation Park
  • Bâtiment F2, Avenue Sécheron 15
  • 1202 Genève
  • Switzerland
+41 058

iOnctura Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iOnctura Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series B) 20-Jun-2024 $102M Completed Clinical Trials - General
10. Later Stage VC 27-Mar-2024 Completed Clinical Trials - General
9. Accelerator/Incubator Completed Clinical Trials - Phase 2
8. Later Stage VC 20-Dec-2022 Completed Clinical Trials - Phase 2
7. Grant 05-Oct-2022 Completed Clinical Trials - Phase 1
6. Debt - General 22-Sep-2022 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A) 14-Jul-2020 Completed Clinical Trials - Phase 1
4. Seed Round 20-Jun-2017 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator Completed Clinical Trials - Phase 1
2. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view iOnctura’s complete valuation and funding history, request access »

iOnctura Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view iOnctura’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

iOnctura Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of next-generation bio-molecules intended for the treatment of cancer and fibrosis. The company's bio-molecule
Drug Discovery
Genève, Switzerland
25 As of 2024

Cambridge, MA

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

iOnctura Competitors (67)

One of iOnctura’s 67 competitors is Aurora Biopharma, a Angel-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aurora Biopharma Angel-Backed Cambridge, MA
NexImmune Formerly VC-backed Gaithersburg, MD
RootPath Venture Capital-Backed Watertown, MA
Memgen Venture Capital-Backed Houston, TX
T3 Pharmaceuticals Formerly VC-backed Allschwil, Switzerland
You’re viewing 5 of 67 competitors. Get the full list »

iOnctura Patents

  • 25

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 13

    Pending

  • Expiring in next 12 mo

iOnctura Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202418087-D0 Biomarkers Pending 10-Dec-2024
GB-202308807-D0 Combinations Inactive 13-Jun-2023
GB-202308112-D0 Combinations Inactive 31-May-2023
GB-202308119-D0 Combinations Inactive 31-May-2023
GB-202308140-D0 Methods of treatment of non-pancreatic gastrointestinal cancers Inactive 31-May-2023 A61K31/437
To view iOnctura’s complete patent history, request access »

iOnctura Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iOnctura Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Syncona Venture Capital Minority
XGEN Venture Impact Investing Minority
European Innovation Council Fund Venture Capital Minority
Horizon 2020 SME Instrument Government
3B Future Health Fund Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial

iOnctura FAQs

  • When was iOnctura founded?

    iOnctura was founded in 2017.

  • Where is iOnctura headquartered?

    iOnctura is headquartered in Genève, Switzerland.

  • What is the size of iOnctura?

    iOnctura has 25 total employees.

  • What industry is iOnctura in?

    iOnctura’s primary industry is Drug Discovery.

  • Is iOnctura a private or public company?

    iOnctura is a Private company.

  • What is iOnctura’s current revenue?

    The current revenue for iOnctura is .

  • How much funding has iOnctura raised over time?

    iOnctura has raised $160M.

  • Who are iOnctura’s investors?

    Syncona, XGEN Venture, European Innovation Council Fund, Horizon 2020 SME Instrument, and 3B Future Health Fund are 5 of 14 investors who have invested in iOnctura.

  • Who are iOnctura’s competitors?

    Aurora Biopharma, NexImmune, RootPath, Memgen, and T3 Pharmaceuticals are some of the 67 competitors of iOnctura.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »